0001209191-23-016074.txt : 20230303 0001209191-23-016074.hdr.sgml : 20230303 20230303203720 ACCESSION NUMBER: 0001209191-23-016074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230301 FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walker Neal CENTRAL INDEX KEY: 0001604457 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 23707239 MAIL ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001604457 Walker Neal C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 1 0 0 0 Common Stock 2023-03-01 4 M 0 96150 A 1271913 D Common Stock 2023-03-01 4 M 0 18275 A 1290188 D Common Stock 2023-03-01 4 M 0 24000 A 1314188 D Common Stock 2023-03-02 4 S 0 29000 12.3651 D 1285188 D Common Stock 2023-03-02 4 M 0 18254 A 1303442 D Common Stock 2023-03-03 4 S 0 30240 12.6346 D 1273202 D Restricted Stock Units 2023-03-01 4 M 0 96150 0.00 D Common Stock 96150 0 D Restricted Stock Units 2023-03-01 4 M 0 18275 0.00 D Common Stock 18275 36550 D Restricted Stock Units 2023-03-01 4 M 0 24000 0.00 D Common Stock 24000 72000 D Restricted Stock Units 2023-03-02 4 M 0 18254 0.00 D Common Stock 18254 18254 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. /s/ Mark Ballantyne, Attorney-in-fact 2023-03-03